I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer

We recently published 10 Stocks Jim Cramer Talked About.  Moderna Inc. (NASDAQ:MRNA) is one of the stocks on Jim Cramer talked about.

Moderna Inc. (NASDAQ:MRNA)’s shares are up by 16% over the past year and by 31% year-to-date. The stock has had a great start to 2026 as the firm made optimistic remarks related to its full-year 2025 revenue. During the JPMorgan Healthcare Conference, Moderna Inc. (NASDAQ:MRNA) raised the revenue guidance to $1.9 billion, which was close to the high end of the previous estimate of $1.6 billion to $2 billion. The firm also cut its operating expenses estimate by $200 million and bumped its cash balance estimate to $8.1 billion. Before the guidance update, Jefferies had kept a Hold rating on Moderna Inc. (NASDAQ:MRNA)’s shares and $30 share price target. The financial firm outlined that Moderna Inc. (NASDAQ:MRNA) should focus on smoothing its coronavirus vaccine business. After the revenue target update, RBC Capital maintained its Sector Perform rating and a $25 share price target. RBC pointed out that Moderna Inc. (NASDAQ:MRNA)’s phase three melanoma trial could be a key catalyst in 2026 and added that headwinds such as optimistic revenue growth guidance and vaccine mandate revision remained. Cramer discussed the revenue target:

“I hope they do it. I hope they do it. That’s been a serial disappointment to me for about eight years now. Sorry.”

While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.